Pharmafile Logo

News and Press Releases

Tiziana Life Sciences Expands Phase 2 Clinical Trial for Non-Active Secondary Progressive Multiple Sclerosis to Additional Prestigious U.S. Medical Centers

4 December 2024 -- New York, US -- Tiziana Life Sciences, Ltd, a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 4, 2024

Tiziana Life Sciences
info@tizianalifesciences.com
Tiziana Life Sciences 14/15 Conduit Street London W1S 2XJ United Kingdom

Treovir Announces Opening of G207 Phase 2 Clinical Trial in Children with Recurrent Brain Tumors

4 December 2024 -- Alabama, US -- Treovir, Inc. announced today the opening of a Phase 2 trial testing G207, an oncolytic HSV immunotherapy, in pediatric brain tumor patients. G207...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: December 4, 2024

Treovir
mchristini@treovir.com

Epsilogen announces initiation of Phase Ib trial of MOv18 IgE

Proof-of-concept study to evaluate the safety, tolerability and efficacy of MOv18 IgE in patients with platinum-resistant ovarian cancer 3 December 2024 -- London, UK -- Epsilogen, the global leader in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 3, 2024

Epsilogen
info@epsilogen.com
Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell disease FRONTIER4 interim phase 3 results evaluating safety profile and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor 3 December 2024 -- Hong Kong, Shanghai and New Jersey, US — HUTCHMED (China) and Innovent Biologics, Inc...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Puma Biotechnology Announces Initiation of ALISCATM-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

20 November 2024 -- California, US -- Puma Biotechnology, Inc, a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCATM-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 20, 2024

Puma Biotechnology
medinfo@pumabiotechnology.com
Los Angeles, California 424-248-6500 Main

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Eight participants achieved HBsAg loss at any time Two participants met criteria for functional cure Two participants who discontinued NUC therapy seroconverted to HBsAb positivity. 15 November 2024 -- Oxford,...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 15, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance

Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes 11 November 2024 -- Strasbourg, France -- AdipoPharma, a biotech company headquartered in France with offices in the US...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2024

AdipoPharma
Nextmed, Bâtiment eXplora (Bureau A203) 2 rue Marie Hamm 67000 Strasbourg France

MMS Named a Finalist in the 2024 Fierce CRO Awards for Leadership in Regulatory Compliance

Zero refusals to file and a SOUL mindset helped solidify the honor 8 November 2024 -- Michigan, US -- MMS, a leading data and regulatory focused clinical research organization (CRO),...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 8, 2024

MMS Holdings
6880 Commerce Blvd. Canton, MI 48187 USA

NorthWest EHealth (NWEH) announces a pilot to test a new model for finding and recruiting participants for clinical trials using the Clinical Practice Research Datalink

The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 5, 2024

NorthWest EHealth
hello@nweh.co.uk
2nd Floor Bright Building Manchester Science Park Pencroft Way Manchester M15 6GZ

Loftware and Signant Health Announce Availability of Integrated Clinical Supplies Labeling Solution

Automates to improve speed, enable compliance, and support scalability 31 October 2024 -- New Hampshire, US -- Loftware, the global leader in Enterprise Labeling and Artwork Management solutions, and Signant Health, the leader in...

Category: Clinical Trials, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: October 31, 2024

Loftware
249 Corporate Dr, Portsmouth, NH 03801

BioPharma Industry Excited about the early use of AI in clinical trials

Experts discuss the long road for complete AI-led transformation at Indegene Digital Summit 202421 October 2024 -- New Jersey, US, and London, UK -- Clinical development experts from Novartis, GSK,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 21, 2024

Indegene
Indegene, Inc. 150 College Rd W Suite 104 Princeton NJ 08540

SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

Transition into clinical-stage development marks a significant corporate and R&D milestone 17 October 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan disease OKYO is the first company to have an IND application granted by...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high,clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer MET is a common biomarker in this setting for patients who develop resistance...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024